CrowdStrike (CRWD) posted a stronger-than-expected earnings report that Ian Tien calls a "bellwether" for the cybersecurity industry. He explains how the company's platformization efforts give it a wider moat against competitors.

NEW YORK , Dec. 3, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, today issued a comprehensive update on its therapeutic pipeline. The Company detailed meaningful progress across HT-001, HT-KIT, HT-ALZ, and its newly launched GDNF-based metabolic program, while continuing to strengthen its global intellectual-property portfolio and expand strategic research partnerships.

LOS ANGELES, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 30, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Synopsys, Inc. (“Synopsys” or the “Company”) (NASDAQ: SNPS) securities between December 4, 2024 and September 9, 2025, inclusive (the “Class Period”).

NEW YORK, NY / ACCESS Newswire / December 3, 2025 / The most dangerous plots never announce themselves. They don't come wrapped in smoke or sirens.

U.S. and Russia failed to reach breakthough on Ukraine peace deal.

FLBR hits a 52-week high as Brazil's stronger currency and equity rally fuel momentum for the Brazil-focused ETF.

Align Technology, Inc. (ALGN) Presents at Evercore 8th Annual Healthcare Conference Transcript

LONDON , Dec. 3, 2025 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company dedicated to the advancement of immunology research and diagnostics, announced today that it has entered into definitive agreements for the purchase and sale of 12,500,000 ordinary shares (or ordinary share equivalents) and preferred investment options to purchase up to an aggregate of 12,500,000 ordinary shares at a purchase price of $0.40 per ordinary share and associated preferred investment option in a private placement . The preferred investment options have an exercise price of $0.40 per ordinary share and will …

CVX enters early talks with Syria on offshore oil and gas exploration as the country seeks to revive its energy infrastructure damaged by years of war.

ETFs like XLG provide a diversified way to benefit from the Mag 7's Q3 earnings surge and the positive momentum expected going forward.

Southwest Gas plans long-term growth with infrastructure upgrades, acquisitions and capital investment.

Tilray's slump deepens as a tighter U.S. hemp rule and a reverse split stir uncertainty despite gains in global cannabis sales.

GE Vernova climbs 3.5% as demand from data centers and gains in wind, gas and power services lift momentum despite supply-chain pressures.

DLTR posts a strong Q3 with earnings and sales beating estimates, 4.2% comps growth and firmer FY25 guidance.

Adjusting sales quotas early in the fiscal year is not surprising, says one analyst who sees weakness in the stock as a buying opportunity.

LOS ANGELES, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming January 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Six Flags Entertainment Corporation (“Six Flags” or the “Company”) (NYSE: FUN) common stock pursuant or traceable to the Company's registration statement and prospectus issued in connection with the July 1, 2024 merger of Six Flags with Cedar Fair, L.P. (“Cedar Fair”), and their subsidiaries and affiliates

LOS ANGELES, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming December 8, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired WPP plc (“WPP” or the “Company”) (NYSE: WPP) common stock between February 22, 2024 and July 8, 2025, inclusive (the “Class Period”). IF YOU SUFFERED A LOSS ON YOUR WPP INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS.

Thermo Fisher expands its Bioprocess Design Centers across Asia, boosting biomanufacturing speed, efficiency and regional innovation.

COO is set to post Q4 earnings as MyDAY momentum offsets Clariti and APAC softness, with revenues and earnings expected to rise.

Globus Medical (GMED) could produce exceptional returns because of its solid growth attributes.